Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ciprofloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | HPGD | P15428 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | TOP2A | P11388 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TOP2B | Q02880 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.73 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | BRD4 | O60885 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.62 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.62 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.62 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ciprofloxacin SCHEMBL2325956 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL29137332 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL2900 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL4459712 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL7994990 | 0.99 | KDM4E (0.98) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL2465661 | 0.99 | KDM4E (0.98) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL1973497 | 0.99 | KDM4E (0.98) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL21519294 | 0.99 | KDM4E (0.98) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL42310 | 0.99 | KDM4E (0.98) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL5618780 | 0.99 | KDM4E (0.98) | KDM4EALDH1A1LMNAHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111135182-A | Antibacterial product and preparation method and application thereof | 心远(广州)药物研究有限公司 | 2020-05-12 | — | — | CN | claimed |
| EP-1408034-B2 | Use of Quinolone and Quinolizinone derivatives as chemotherapeutic agents | BAYER INNOVATION GMBH (DE) | 2011-05-25 | — | — | EP | claimed |
| EP-4294521-A1 | METHODS AND SYSTEMS FOR DETERMINING SUITABILITY OF COMPOSITIONS FOR INHIBITING GROWTH OF POLYMICROBIAL SAMPLES | Cap Diagnostics, LLC, DBA Pathnostics (US) | 2023-12-27 | — | — | EP | disclosed |
| US-20230392185-A1 | METHODS AND SYSTEMS FOR DETERMINING SUITABILITY OF COMPOSITIONS FOR INHIBITING GROWTH OF POLYMICROBIAL SAMPLES | CAP Diagnostics, LLC, dba Pathnostics | 2023-12-07 | — | — | US | disclosed |
| US-20230357817-A1 | METHODS FOR TREATING POLYMICROBIAL INFECTIONS | CAP Diagnostics, LLC, dba Pathnostics | 2023-11-09 | — | — | US | disclosed |
| US-20230357818-A1 | METHODS FOR TREATING POLYMICROBIAL INFECTIONS | CAP Diagnostics, LLC, dba Pathnostics | 2023-11-09 | — | — | US | disclosed |
| US-11746371-B2 | Methods for treating polymicrobial infections | CAP Diagnostics, LLC (US) | 2023-09-05 | — | — | US | disclosed |
| US-11541029-B2 | High penetration compositions and their applications | TECHFIELDS PHARMA CO., LTD. (CN) | 2023-01-03 | — | — | US | disclosed |
| US-20220411782-A1 | PHAGE COMPOSITIONS COMPRISING CRISPR-CAS SYSTEMS AND METHODS OF USE THEREOF | Locus Biosciences, Inc. | 2022-12-29 | — | — | US | disclosed |
| US-20220315975-A1 | METHODS AND SYSTEMS FOR PREPARING THERAPEUTIC SOLUTIONS FOR POLYMICROBIAL INFECTIONS | BANK OF HOPE | 2022-10-06 | — | — | US | disclosed |
| WO-2022178142-A1 | METHODS AND SYSTEMS FOR DETERMINING SUITABILITY OF COMPOSITIONS FOR INHIBITING GROWTH OF POLYMICROBIAL SAMPLES | CAP Diagnostics, LLC, dba Pathnostics (US) | 2022-08-25 | — | — | WO | disclosed |
| US-5409898-A | Synergistic composition containing beta-lactam antibiotic and cationic polypeptide | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-04-25 | — | — | US | disclosed |
| US-5260066-A | Cryogel bandage containing therapeutic agent | SRCHEM INCORPORATED (US) | 1993-11-09 | — | — | US | disclosed |
| EP-0559647-A1 | COMPOSITION AND TREATMENT WITH BIOLOGICALLY ACTIVE PEPTIDES AND ANTIBIOTICS WHICH INHIBIT DNA GYRASE | MAGAININ PHARMACEUTICALS INC. (US) | 1993-09-15 | — | — | EP | disclosed |
| EP-0559647-A4 | COMPOSITION AND TREATMENT WITH BIOLOGICALLY ACTIVE PEPTIDES AND ANTIBIOTICS WHICH INHIBIT DNA GYRASE. | MAGAININ PHARMA (US) | 1993-07-15 | — | — | EP | disclosed |
| US-5208220-A | Biological antigrowth agent | MAGAININ PHARMACEUTICALS, INC. (US) | 1993-05-04 | — | — | US | disclosed |
| EP-0516747-A4 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS CAUSED BY ORGANISMS SENSITIVE TO -G(B)-LACTAM ANTIBIOTICS | — | 1993-03-24 | — | — | EP | disclosed |
| EP-0516747-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS CAUSED BY ORGANISMS SENSITIVE TO $g(b)-LACTAM ANTIBIOTICS | Bristol-Myers Squibb Company (US) | 1992-12-09 | — | — | EP | disclosed |
| WO-1992000090-A1 | COMPOSITION AND TREATMENT WITH BIOLOGICALLY ACTIVE PEPTIDES AND ANTIBIOTICS WHICH INHIBIT DNA GYRASE | MAGAININ PHARMACEUTICALS INC. (US) | 1992-01-09 | — | — | WO | disclosed |
| WO-1991012815-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS CAUSED BY ORGANISMS SENSITIVE TO β-LACTAM ANTIBIOTICS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1991-09-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11541029-B2 | High penetration compositions and their applications | SLC19A1, HIRA, SLC43A1 | KDM4E 4307/4885ALDH1A1 829/4885LMNA 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.